Core Insights - Anixa Biosciences is focused on cancer treatment and prevention, featuring its Chairman and CEO, Dr. Amit Kumar, on the Water Tower Research Healthcare Happenings podcast to discuss positive clinical trial data for its breast cancer vaccine and ovarian cancer CAR-T therapy [1] Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company specializing in cancer treatment and prevention [1] - The company's therapeutic portfolio includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology [1] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [1] Technology and Collaboration - The CAR-T technology used by Anixa is differentiated by its mechanism, where the natural ligand of the FSHR receptor binds to tumor cells instead of using an antibody fragment [1] - Anixa partners with renowned research institutions to explore emerging technologies for further development and commercialization [1] Financial and Future Outlook - Dr. Kumar discussed the financial condition of the company and future plans during the podcast, indicating a focus on advancing their clinical programs [1]

NASDAQ:ANIX March 10, 2026 Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences' current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to iden ...

NASDAQ:ANIX March 2026 Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences' current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify ...

Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other ju ...

Core Insights - Anixa Biosciences has received a Notice of Allowance for a patent from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology, marking the first Korean patent for this platform [1] - The patent, titled "Vaccine Adjuvants and Formulations," provides composition of matter protection and is expected to enhance Anixa's global intellectual property portfolio [1] - The company aims to leverage this patent to pursue international commercialization opportunities and potential partnerships with larger pharmaceutical firms [1] Patent and Technology - The newly allowed patent reinforces Anixa's leadership in cancer immunotherapy and complements existing patents in the United States and other jurisdictions [1] - The breast cancer vaccine technology is based on immunizing against human -lactalbumin, a protein associated with lactation, which is aberrantly expressed in certain breast cancer types [1] - Anixa's vaccine has shown promising results in a Phase 1 clinical trial, meeting all major primary endpoints and generating immune responses in 74% of participants [1] Market Context - Breast cancer incidence rates are rising in South Korea, with a notable trend of earlier onset compared to Western nations [1] - Breast cancer remains the most commonly diagnosed cancer among women globally, and there are currently no approved vaccines for its prevention [1] - Anixa's approach aims to transform cancer prevention strategies, particularly for aggressive forms like triple-negative breast cancer [1] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [1] - The company partners with renowned research institutions to develop vaccines targeting various cancers, including breast and ovarian cancer [1] - Anixa's business model emphasizes collaboration at all stages of development, allowing for the exploration of emerging technologies in complementary fields [1]

Core Insights - Anixa Biosciences will host its 2026 Annual Meeting of Stockholders on March 10, 2026, in a virtual format, which will be open to all interested parties, including non-stockholders [1] - The meeting will feature a corporate update from Anixa's Chairman and CEO, Dr. Amit Kumar, highlighting recent clinical milestones in the oncology pipeline [1] Clinical Progress - The final Phase 1 data from the breast cancer vaccine program met primary endpoints, demonstrating favorable tolerability and immune responses in the majority of participants [1] - Encouraging survival observations were reported in the ongoing Phase 1 ovarian cancer CAR-T trial, along with regulatory approval for substantial dose escalation [1] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel) for ovarian cancer [1] - The company collaborates with Moffitt Cancer Center to develop a novel CAR-T technology, which utilizes the natural ligand of the FSHR receptor [1] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers [1]

Core Insights - Anixa Biosciences, Inc. is focused on cancer treatment and prevention, with a key highlight being Dr. Jose Conejo-Garcia's keynote speech at the SCTR 2026 Retreat, discussing the company's CAR-T technology and ongoing clinical trials [1][2]. Group 1: Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [5]. - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor instead of an antibody fragment [5]. - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers, focusing on immunizing against specific proteins expressed in certain cancer forms [5]. Group 2: Clinical Trials and Research - The ongoing Phase 1 clinical trial of lira-cel targets adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, utilizing the FSHR-mediated CAR-T therapy [4]. - Dr. Conejo-Garcia's presentation at the SCTR 2026 Retreat will cover the advancements and findings from the ongoing clinical trial of lira-cel [2]. Group 3: Industry Collaboration - The SCTR 2026 Retreat aims to foster collaboration among pioneers in research, clinical care, and industry, showcasing innovations in advanced cell therapy, immune therapy, and oncology [3].

Summary of Anixa Biosciences Fireside Chat Company Overview - **Company**: Anixa Biosciences (NasdaqCM: ANIX) - **Industry**: Biotechnology - **Focus**: Development of CAR T cell therapy for ovarian cancer and a breast cancer vaccine - **Clinical Stage**: Engaged in clinical trials for cancer therapies Key Achievements in 2025 - **Phase 1 Breast Cancer Vaccine Trial**: Completed in collaboration with Cleveland Clinic and U.S. Department of Defense, with data presented in December 2025 [5][6] - **CAR T Therapy Progress**: Significant patient outcomes reported, with advancements in clinical trials and patent approvals [5][6] - **Official Naming**: CAR T therapy received official name approval from domestic and international organizations [6] Upcoming Milestones - **Transition to Phase 2 for Breast Cancer Vaccine**: Requires FDA report submission and discussions, with plans to enroll 80-100 women [7][10] - **Manufacturing Plans**: Working with manufacturers to produce larger vaccine quantities under GLP and GMP conditions [7][8] Financial Overview - **Cash Burn**: $7 million in the last fiscal year, with an expected increase to approximately $8 million for the upcoming year [11][12] - **Cash Reserves**: $15 million cash balance with no debt, providing over two years of operational runway [12][13] CAR T Therapy Developments - **Safety and Efficacy**: Phase 1 trial focused on safety, with promising early efficacy indicators; patients have outlived expected life expectancy [16][18] - **Patient Outcomes**: Some patients lived significantly longer than the median survival of 12 weeks, with one patient living 28 months [18][19] - **Regulatory Approval**: Seeking IRB approval to escalate dosages due to positive safety profile [19] Mechanisms of Action - **Unique Targeting**: CAR T therapy targets a unique protein present only on cancer cells, minimizing effects on healthy tissues [22] - **Anti-Angiogenesis Effect**: Potential destruction of tumor vasculature, enhancing treatment efficacy [23] - **Peritoneal Delivery**: Direct delivery to the peritoneal cavity improves therapy effectiveness and reduces systemic side effects [24] Lymphodepletion Strategy - **Introduction of Lymphodepletion**: Planned to enhance CAR T cell engraftment and proliferation, with careful monitoring of associated risks [31][33] - **Comparative Analysis**: Some cohorts will receive lymphodepletion while others will not, to evaluate its impact on patient outcomes [33] Expectations for 2026 - **Pivotal Year**: Anticipation of significant data from CAR T trials and breast cancer vaccine Phase 2 initiation [36][38] - **Control Arm in Phase 2**: Designed to evaluate the vaccine's efficacy against a control group [38] - **Fiscal Responsibility**: Commitment to maintaining financial prudence while advancing clinical trials [39] Conclusion - **Outlook**: 2026 is expected to be a busy and eventful year for Anixa, with critical data releases and potential partnerships on the horizon [39][40]

Core Insights - Anixa Biosciences is reporting promising outcomes from its ongoing Phase 1 clinical trial of CAR-T therapy for recurrent ovarian cancer, with several patients exceeding expected survival rates at low dose levels [1][2][3] Group 1: Trial Overview - The Phase 1 trial is focused on adult women with recurrent ovarian cancer who have not responded to standard chemotherapy and have progressed after two or more therapies [2] - Twelve patients have been treated at four dosage levels, with seven patients living beyond the expected median survival of three to four months [2] - Notably, one patient survived 28 months post-treatment, and three others have survived over one year [2] Group 2: Safety and Efficacy - The trial primarily aims to demonstrate safety, and the absence of dose-limiting toxicities (DLTs) has allowed for significant dose escalation [3][5] - The dosing may increase from 1×10 to as high as 1×10 CAR-positive cells per kilogram, representing a two-order-of-magnitude increase [3] - The favorable safety profile is attributed to the intra-peritoneal delivery method, which may enhance localized tumor targeting while reducing systemic toxicity [3] Group 3: Future Directions - The next patient cohort will receive higher doses following a lymphodepletion regimen, which is expected to create a more favorable environment for CAR-T cell activity [4] - The regulatory approval for the protocol amendment allows for further evaluation of both safety and potential therapeutic benefits as the study progresses [5] - Anixa plans to discuss trial observations and future plans in an upcoming fireside chat on February 10, 2026 [1][6] Group 4: Technology and Collaboration - Anixa's CAR-T therapy, lira-cel, targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells and certain cancer cells [7] - The company collaborates with Moffitt Cancer Center, a leader in cancer immunotherapy, to develop its CAR-T therapy and other cancer vaccines [8]

Core Insights - Anixa Biosciences, Inc. has provided an update on its Phase 1 ovarian cancer CAR-T clinical trial, highlighting positive patient outcomes following a protocol amendment that allows for significant dose escalation [1] Trial Overview - The trial involves liraltagene autoleucel (lira-cel), which targets the follicle-stimulating hormone receptor (FSHR) selectively expressed on ovarian cells and certain cancer cells, while sparing healthy tissue [2] - The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer who have not responded to standard chemotherapy and have progressed after two or more prior therapies [2] Patient Outcomes - Twelve patients have been treated at four dosage levels, with seven patients surviving beyond the expected median survival of approximately three to four months [3] - Notably, one patient survived 28 months post-treatment, while three others survived over one year (17, 15, and 14 months respectively) [4] Safety Profile - No dose-limiting toxicities (DLTs) have been observed, leading to the approval of a protocol amendment for significant dose escalation [5] - The favorable safety profile is believed to be partly due to the direct intra-peritoneal delivery of CAR-T cells, which may reduce systemic toxicity and enhance localized tumor targeting [6] Protocol Amendment - The amended protocol allows dosing to increase from 1×10⁵ to 1×10⁹ CAR-positive cells per kilogram of body weight, representing a two-order-of-magnitude increase [7] - The next patient cohort will receive 1×10⁷ cells/kg following a lymphodepletion regimen with cyclophosphamide and fludarabine [7] Lymphodepletion - Lymphodepletion is intended to reduce competing immune cells, creating a more favorable environment for CAR-T expansion and activity, although its role in solid tumors remains investigational [8] Market Reaction - Anixa Biosciences shares increased by 1.69% to $3.01 during premarket trading [8]